439 related articles for article (PubMed ID: 29683098)
21. miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges.
Zhou SS; Jin JP; Wang JQ; Zhang ZG; Freedman JH; Zheng Y; Cai L
Acta Pharmacol Sin; 2018 Jul; 39(7):1073-1084. PubMed ID: 29877320
[TBL] [Abstract][Full Text] [Related]
22. 2-hydroxycaproate predicts cardiovascular mortality in patients with atherosclerotic disease.
Cardellini M; Ballanti M; Davato F; Cardolini I; Guglielmi V; Rizza S; Pecchioli C; Casagrande V; Mavilio M; Porzio O; Legramante JM; Ippoliti A; Farcomeni A; Sbraccia P; Menghini R; Dumas ME; Kappel BA; Federici M
Atherosclerosis; 2018 Oct; 277():179-185. PubMed ID: 29958653
[TBL] [Abstract][Full Text] [Related]
23. Understanding different facets of cardiovascular diseases based on model systems to human studies: a proteomic and metabolomic perspective.
Basak T; Varshney S; Akhtar S; Sengupta S
J Proteomics; 2015 Sep; 127(Pt A):50-60. PubMed ID: 25956427
[TBL] [Abstract][Full Text] [Related]
24. Functional Metabolomics Characterizes a Key Role for
Zhang L; Wei TT; Li Y; Li J; Fan Y; Huang FQ; Cai YY; Ma G; Liu JF; Chen QQ; Wang SL; Li H; Alolga RN; Liu B; Zhao DS; Shen JH; Wang XM; Zhu W; Li P; Qi LW
Circulation; 2018 Mar; 137(13):1374-1390. PubMed ID: 29212895
[TBL] [Abstract][Full Text] [Related]
25. The Use of High Sensitivity C-Reactive Protein in Cardiovascular Disease Detection.
Castro AR; Silva SO; Soares SC
J Pharm Pharm Sci; 2018; 21(1):496-503. PubMed ID: 30496036
[TBL] [Abstract][Full Text] [Related]
26. Can Untargeted Metabolomics Be Utilized in Drug Discovery/Development?
Caldwell GW; Leo GC
Curr Top Med Chem; 2017; 17(24):2716-2739. PubMed ID: 28685690
[TBL] [Abstract][Full Text] [Related]
27. Lipidomic insight into cardiovascular diseases.
Kohno S; Keenan AL; Ntambi JM; Miyazaki M
Biochem Biophys Res Commun; 2018 Oct; 504(3):590-595. PubMed ID: 29665359
[TBL] [Abstract][Full Text] [Related]
28. New technologies personalize diagnostics and therapeutics.
Rosenson RS
Curr Atheroscler Rep; 2010 May; 12(3):184-6. PubMed ID: 20425257
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches.
Niiranen TJ; Vasan RS
Expert Rev Cardiovasc Ther; 2016 Jul; 14(7):855-69. PubMed ID: 27057779
[TBL] [Abstract][Full Text] [Related]
30. New and emerging biomarkers in cardiovascular disease.
Cahill LE; Bertoia ML; Aroner SA; Mukamal KJ; Jensen MK
Curr Diab Rep; 2015 Nov; 15(11):88. PubMed ID: 26370699
[TBL] [Abstract][Full Text] [Related]
31. [The role of -omics technology in the pathophysiology, diagnosis, and treatment of cardiovascular diseases].
Sinan ÜY; Unlu S
Turk Kardiyol Dern Ars; 2017 Jul; 45(5):470-484. PubMed ID: 28694404
[TBL] [Abstract][Full Text] [Related]
32. Metabolic phenotyping and cardiovascular disease: an overview of evidence from epidemiological settings.
Iliou A; Mikros E; Karaman I; Elliott F; Griffin JL; Tzoulaki I; Elliott P
Heart; 2021 Jul; 107(14):1123-1129. PubMed ID: 33608305
[TBL] [Abstract][Full Text] [Related]
33. Genomic medicine in the prevention and treatment of atherosclerotic cardiovascular disease.
Tuteja S; Rader DJ
Per Med; 2012 Jun; 9(4):395-404. PubMed ID: 29776260
[TBL] [Abstract][Full Text] [Related]
34. Developing and assessing cardiovascular biomarkers.
Dadu RT; Nambi V; Ballantyne CM
Transl Res; 2012 Apr; 159(4):265-76. PubMed ID: 22424430
[TBL] [Abstract][Full Text] [Related]
35. Integrated metabolomics and metallomics analyses in acute coronary syndrome patients.
Yin X; de Carvalho LP; Chan MY; Li SFY
Metallomics; 2017 Jun; 9(6):734-743. PubMed ID: 28518204
[TBL] [Abstract][Full Text] [Related]
36. [Metabolomic Profiling of Patients With Cardiovascular Diseases].
Belenkov YN; Privalova EV; Kozhevnikova MV; Korobkova EO; Ilgisonis IS; Kaplunova VY; SHakaryants GA; Appolonova SA; Kuharenko AV; Larcova EV; Mesonzhik NV
Kardiologiia; 2018 Sep; 58(9):59-62. PubMed ID: 30295200
[TBL] [Abstract][Full Text] [Related]
37. Biomarkers of vulnerable atheromatous plaques: translational medicine perspectives.
Wang X; Connolly TM
Adv Clin Chem; 2010; 50():1-22. PubMed ID: 20521438
[TBL] [Abstract][Full Text] [Related]
38. Novel methodologies for biomarker discovery in atherosclerosis.
Hoefer IE; Steffens S; Ala-Korpela M; Bäck M; Badimon L; Bochaton-Piallat ML; Boulanger CM; Caligiuri G; Dimmeler S; Egido J; Evans PC; Guzik T; Kwak BR; Landmesser U; Mayr M; Monaco C; Pasterkamp G; Tuñón J; Weber C;
Eur Heart J; 2015 Oct; 36(39):2635-42. PubMed ID: 26049157
[TBL] [Abstract][Full Text] [Related]
39. The role of metabolites and metabolomics in clinically applicable biomarkers of disease.
Mamas M; Dunn WB; Neyses L; Goodacre R
Arch Toxicol; 2011 Jan; 85(1):5-17. PubMed ID: 20953584
[TBL] [Abstract][Full Text] [Related]
40. MicroRNAs Determining Inflammation as Novel Biomarkers and Potential Therapeutic Targets.
Kotsinas A; Sigala F; Garbis SD; Galyfos G; Filis K; Vougas K; Papalampros A; Johnson EE; Chronopoulos E; Georgakilas AG; Gorgoulis VG
Curr Med Chem; 2015; 22(22):2666-79. PubMed ID: 26180004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
